{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-228956","form_type":"8-K/A","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2026-05-18T20:20:26+00:00","discovered_at":"2026-05-18T20:21:00.298108+00:00","generated_at":"2026-05-18T20:21:39.759821+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Quince reports positive Phase 2a LAM-001 data in PH-ILD; 6MWD +67.4m, PVR -33.9%","bullets":["Phase 2a open-label trial in PH-ILD (n=4 evaluable) on stable treprostinil showed 6MWD increase of 67.4 meters and PVR reduction of 33.9% at 24 weeks.","All evaluable PH-ILD patients improved from Functional Class III to II by Week 24; LAM-001 was generally well tolerated.","Phase 2b trial in PH-ILD to begin mid-2026 with topline data expected in Q1 2028.","8-K/A corrects sign errors in original press release table for PVR percentages (now shown as -35.3% and -33.9% for evaluable population and PH-ILD subgroup respectively).","LAM-001 is an inhaled mTOR inhibitor acquired from Orphai Therapeutics; Quince plans to continue development in PH-ILD."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-228956","json":"https://secwatch.observer/filing/0001193125-26-228956.json","markdown":"https://secwatch.observer/filing/0001193125-26-228956.md","text":"https://secwatch.observer/filing/0001193125-26-228956.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526228956/0001193125-26-228956-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526228956/d135388d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T20:21:39.759821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}